La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Amryt Pharma Résultats passés
Passé contrôle des critères 0/6
Amryt Pharma has been growing earnings at an average annual rate of 34.4%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been growing at an average rate of 32.7% per year.
Informations clés
34.4%
Taux de croissance des bénéfices
59.1%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 6.0% |
| Taux de croissance des recettes | 32.7% |
| Rendement des fonds propres | -0.2% |
| Marge nette | -0.3% |
| Dernière mise à jour des bénéfices | 30 Sep 2022 |
Mises à jour récentes des performances passées
Recent updates
Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU
Oct 18Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval
Sep 16Amryt gets British marketing approval & orphan drug designation for rare skin disease gel
Sep 08Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
Jul 14Amryt's Filsuvez gets approval in EU to treat rare skin disorder
Jun 23Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions
Dec 09Chiasma surges on merger agreement with Amryt
May 05Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept
Feb 04Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder
Dec 23Amryt Group's Lojuxta receives marketing approval in Brazil
Dec 09Ventilation des recettes et des dépenses
Comment Amryt Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 22 | 244 | -1 | 124 | 38 |
| 30 Jun 22 | 239 | 3 | 119 | 41 |
| 31 Mar 22 | 233 | 3 | 112 | 39 |
| 31 Dec 21 | 223 | 1 | 100 | 38 |
| 30 Sep 21 | 210 | -88 | 90 | 34 |
| 30 Jun 21 | 203 | -81 | 83 | 30 |
| 31 Mar 21 | 186 | -92 | 82 | 28 |
| 31 Dec 20 | 183 | -105 | 81 | 28 |
| 30 Sep 20 | 180 | -87 | 80 | 31 |
| 30 Jun 20 | 140 | -92 | 68 | 26 |
| 31 Mar 20 | 98 | -87 | 52 | 23 |
| 31 Dec 19 | 58 | -63 | 36 | 16 |
| 31 Dec 18 | 17 | -30 | 18 | 11 |
Des revenus de qualité: AMYT is currently unprofitable.
Augmentation de la marge bénéficiaire: AMYT is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AMYT is unprofitable, but has reduced losses over the past 5 years at a rate of 34.4% per year.
Accélération de la croissance: Unable to compare AMYT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: AMYT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Rendement des fonds propres
ROE élevé: AMYT has a negative Return on Equity (-0.24%), as it is currently unprofitable.